These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25679136)

  • 1. Psychosis associated with guanfacine.
    Kim RK; Chayer R
    J Clin Psychopharmacol; 2015 Apr; 35(2):213. PubMed ID: 25679136
    [No Abstract]   [Full Text] [Related]  

  • 2. Does guanfacine trigger mania in children?
    Horrigan JP; Barnhill LJ
    J Child Adolesc Psychopharmacol; 1998; 8(2):149-50. PubMed ID: 9730081
    [No Abstract]   [Full Text] [Related]  

  • 3. Growth hormone response to guanfacine in boys with attention deficit hyperactivity disorder: a preliminary study.
    Halperin JM; Newcorn JH; McKay KE; Siever LJ; Sharma V
    J Child Adolesc Psychopharmacol; 2003; 13(3):283-94. PubMed ID: 14642016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guanfacine use in children with attention deficit hyperactivity disorder.
    Cohn LM; Caliendo GC
    Ann Pharmacother; 1997; 31(7-8):918-9. PubMed ID: 9220058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanfacine extended release in the treatment of attention-deficit/hyperactivity disorder.
    Rostain AL
    Curr Psychiatry Rep; 2009 Oct; 11(5):339-40. PubMed ID: 19785972
    [No Abstract]   [Full Text] [Related]  

  • 6. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Connor DF; Rubin J
    Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of suspected alphagan-induced psychosis.
    Kim DD
    Arch Ophthalmol; 2000 Aug; 118(8):1132-3. PubMed ID: 10922214
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Sallee FR; Lyne A; Wigal T; McGough JJ
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):215-26. PubMed ID: 19519256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
    Posey DJ; Puntney JI; Sasher TM; Kem DL; McDougle CJ
    J Child Adolesc Psychopharmacol; 2004; 14(2):233-41. PubMed ID: 15319020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case series on the heightened autonomic response due to guanfacine and amphetamine interaction.
    Gaiser EC; Matuskey D; Perkins E; D'Amico C; Abdelghany O; McKee SA; Cosgrove KP
    J Clin Psychopharmacol; 2015 Apr; 35(2):197-9. PubMed ID: 25634160
    [No Abstract]   [Full Text] [Related]  

  • 11. Does guanfacine cause hallucinations in children?
    Luthra V; Markov D; Ambrosini P
    J Child Adolesc Psychopharmacol; 1999; 9(4):313-4. PubMed ID: 10630462
    [No Abstract]   [Full Text] [Related]  

  • 12. Guanfacine in children with autism and/or intellectual disabilities.
    Handen BL; Sahl R; Hardan AY
    J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanfacine for Tourette's disorder.
    Fras I
    J Am Acad Child Adolesc Psychiatry; 1996 Jan; 35(1):3-4. PubMed ID: 8567607
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms.
    Stahl SM
    J Clin Psychiatry; 2010 Mar; 71(3):223-4. PubMed ID: 20331927
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased plasma valproate concentrations when coadministered with guanfacine.
    Ambrosini PJ; Sheikh RM
    J Child Adolesc Psychopharmacol; 1998; 8(2):143-7. PubMed ID: 9730080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In the pipeline: non-stimulant ADHD meds.
    Glazer WM
    Behav Healthc; 2010 Jan; 30(1):30-1. PubMed ID: 20184258
    [No Abstract]   [Full Text] [Related]  

  • 18. Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder.
    Scahill L; Barloon L; Farkas L
    J Child Adolesc Psychiatr Nurs; 1999; 12(4):168-73. PubMed ID: 10876518
    [No Abstract]   [Full Text] [Related]  

  • 19. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.
    Scahill L
    CNS Drugs; 2009; 23 Suppl 1():43-9. PubMed ID: 19621977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyperactivity in children with pervasive developmental disorders.
    Scahill L; Pachler M
    J Child Adolesc Psychiatr Nurs; 2007 Feb; 20(1):59-62. PubMed ID: 17284238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.